Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

4.47
+0.38009.29%
Volume:277.24K
Turnover:1.21M
Market Cap:406.41M
PE:-2.39
High:4.50
Open:4.08
Low:3.99
Close:4.09
52wk High:8.54
52wk Low:1.35
Shares:90.92M
Float Shares:64.61M
Volume Ratio:1.75
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8726
EPS(LYR):-5.5878
ROE:-75.99%
ROA:-22.85%
PB:2.18
PE(LYR):-0.80

Loading ...

X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice

Reuters
·
Mar 20

Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)

TIPRANKS
·
Mar 18

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 17

Rpt-X4 Pharmaceuticals Q4 EPS USD -0.22

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals Inc - Cash Runway Expected Through 2028

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals Inc - Global 4Ward Phase 3 Chronic Neutropenia Trial on Track to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals FY 2025 net loss widens 111.2% to USD 79.2 million as revenue rises 1,250% to USD 35.1 million

Reuters
·
Mar 17

X4 Pharmaceuticals Initiated at Buy by Guggenheim

Dow Jones
·
Mar 09

X4 Pharmaceuticals initiated with a Buy at Guggenheim

TIPRANKS
·
Mar 09

X4 Pharmaceuticals Receives Positive Opinion From the Ema Chmp Recommending Approval of Mavorixafor in the EU for Whim Syndrome

THOMSON REUTERS
·
Feb 27

X4 Pharmaceuticals: Positive Opinion Will NOW Be Reviewed by European Commission (Ec) With a Final Approval Decision Anticipated in Q2 of 2026

THOMSON REUTERS
·
Feb 27

EMA CHMP recommends EU approval of X4 Pharmaceuticals’ mavorixafor for WHIM syndrome

Reuters
·
Feb 27

X4 Pharmaceuticals to Join Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 03

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

X4 Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 03

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 03

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
Dec 24, 2025

X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 10, 2025

X4 Pharmaceuticals to Join Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 06, 2025

X4 Pharma Q3 net loss narrows to $29.8 mln

Reuters
·
Nov 05, 2025